<DOC>
	<DOC>NCT00724698</DOC>
	<brief_summary>Eligible patients will be prescribed Desloratadine 1 tablet of 5 mg once daily. Patients will be asked to follow-up for a final visit after 14 days (Day 15) where the safety, tolerability and clinical efficacy will be measured.</brief_summary>
	<brief_title>Evaluation of Desloratadine When Used in Patients With Either Allergic Rhinitis or Chronic Idiopathic Urticaria</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Urticaria</mesh_term>
	<mesh_term>Desloratadine</mesh_term>
	<criteria>Outpatient men or women, age 12 years and above. Diagnosis of Allergic Rhinitis or Chronic Idiopathic Urticaria Known hypersensitivity to Desloratadine. Pregnancy or lactation</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>